The best guess approach to phase I trial designROSA, Daniela D; HARRIS, John; JAYSON, Gordon C et al.Journal of clinical oncology. 2006, Vol 24, Num 1, pp 206-208, issn 0732-183X, 3 p.Article

TCNU: a ray of hope for designer nitrosoureas?WORKMAN, P.European journal of cancer & clinical oncology. 1987, Vol 23, Num 12, pp 1823-1828, issn 0277-5379Article

Phase I trial of teroxironeNEIDHART, J. A; DEROCHER, D; GREVER, M. R et al.Cancer treatment reports. 1984, Vol 68, Num 9, pp 1115-1119, issn 0361-5960Article

PENTAMETHYLMELAMINE (PMM): PHASE I CLINICAL AND PHARMACOKINETIC STUDIES = PENTAMETHYLMELAMINE: ETUDE CLINIQUE PHASE I ET PHARMACOCINETIQUEMUINDI JRF; NEWELL DR; SMITH IE et al.1983; BRITISH JOURNAL OF CANCER; ISSN 0007-0920; GBR; DA. 1983; VOL. 47; NO 1; PP. 27-33; ABS. ENG; BIBL. 26 REF.; GRAPHArticle

A PHASE I AND CLINICAL PHARMACOLOGY STUDY OF INTRAVENOUSLY ADMINISTERED CARMINOMYCIN IN CANCER PATIENTS IN THE UNITED STATESCOMIS RL; ISSELL BF; PITTMAN K et al.1982; CANCER RES.; ISSN 0008-5472; USA; DA. 1982; VOL. 42; NO 7; PP. 2944-2948; BIBL. 15 REF.Article

Multi-Institutional Phase I Trials of Anticancer AgentsDOWLATI, Afshin; MANDA, Sudhir; GIBBONS, Joseph et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1926-1931, issn 0732-183X, 6 p.Article

A phase I clinical tolerance study of rDNA alpha₂ human interferon in patients with non-reticuloendothelial system malignancies = Etude clinique phase I de la tolérance de l'interféron leucocytaire humain alpha 2 recombinant chez les sujets ayant une affection maligne réticulo-endothélialeEDELSTEIN, M. B; SCHELLEKENS, H; LAURENT, T et al.European journal of cancer & clinical oncology. 1983, Vol 19, Num 7, pp 891-894, issn 0277-5379Article

Phase I study of a new anthraquinone derivative, mitoxantrone = Etude phase I d'une nouvelle anthraquinone, la mitoxantroneOGAWA, M; SAITO, T; WAKUI, A et al.Monograph series of the European Organization for Research on Treatment of Cancer. 1983, Vol 12, pp 85-91, issn 0146-0447Article

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial DiscussionsJENKINS, Valerie; SOLIS-TRAPALA, Ivonne; LANGRIDGE, Carolyn et al.Journal of clinical oncology. 2011, Vol 29, Num 1, pp 61-68, issn 0732-183X, 8 p.Article

Translation of innovative designs into phase I trialsROGATKO, André; SCHOENECK, David; JONAS, William et al.Journal of clinical oncology. 2007, Vol 25, Num 31, pp 4982-4986, issn 0732-183X, 5 p.Article

PHASE I TRIAL OF INDICINE-N-OXIDE ON TWO DOSE SCHEDULES = ESSAI PHASE I DE L'INDICINE-N-OXYDE SELON DEUX PROTOCOLES DIFFERENTSTAYLOR S; BELT RJ; HAAS CD et al.1983; CANCER; ISSN 0008-543X; USA; DA. 1983; VOL. 51; NO 11; PP. 1988-1991; ABS. ENG; BIBL. 4 REF.; GRAPHArticle

FINAL REPORT ON THE UNITED STATES PHASE 1 CLINICAL TRIAL OF THE HYPOXIC CELL RADIOSENSITIZER, MISONIDAZOLE (R0-07-0582; NSC#261037)PHILLIPS TL; WASSERMAN TH; JOHNSON RJ et al.1981; CANCER; ISSN 0008-543X; USA; DA. 1981; VOL. 48; NO 8; PP. 1697-1704; BIBL. 15 REF.Article

ADRIAMYCIN (NSC-123127) PLUS 5-FLUOROURACIL (NSC-19893)= A PHASE I STUDYTRANUM BL; STEPHENS RL; LEHANE DE et al.1975; CANCER CHEMOTHERAPY REP., 1; U.S.A.; DA. 1975; VOL. 59; NO 6; PP. 1163-1165; BIBL. 9 REF.Article

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center InitiativeTSIMBERIDOU, Apostolia-Maria; ISKANDER, Nancy G; YANG YE et al.Clinical cancer research (Print). 2012, Vol 18, Num 22, pp 6373-6383, issn 1078-0432, 11 p.Article

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistCINES, Douglas B; JENKINS, Julian M; WILLIAMS, Daphne et al.Blood. 2007, Vol 109, Num 11, issn 0006-4971, 4591-4592, 4739-4741 [5 p.]Article

A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agentRADEMAKER-LAKHAI, Jeany M; VAN DEN BONGARD, Desiree; PLUIM, Dick et al.Clinical cancer research. 2004, Vol 10, Num 11, pp 3717-3727, issn 1078-0432, 11 p.Article

Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose control in PNU-214936CHENG, Jonathan D; BABB, James S; WEINER, Louis M et al.Journal of clinical oncology. 2004, Vol 22, Num 4, pp 602-609, issn 0732-183X, 8 p.Article

Phase I and pharmacokinetic study of brequinar (DUP 785 ; NSC 368390) in cancer patientsDE FORNI, M; CHABOT, G. G; ARMAND, J.-P et al.European journal of cancer. Part A. 1993, Vol 29, Num 7, pp 983-988Article

Adverse events in phase one studies : a study in 430 healthy volunteersSIBILLE, M; DEIGAT, N; OLAGNIER, V et al.European journal of clinical pharmacology. 1992, Vol 42, Num 4, pp 389-393, issn 0031-6970Article

Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641)HAINSWORTH, J. D; HANDE, K. R; SATTERLEE, W. G et al.Cancer research (Baltimore). 1989, Vol 49, Num 18, pp 5217-5220, issn 0008-5472, 4 p.Article

Phase I clinical and pharmacologic trial of carboplatin daily for 5 daysVAN ECHO, D. A; EGORIN, M. J; WHITACRE, M. Y et al.Cancer treatment reports. 1984, Vol 68, Num 9, pp 1103-1114, issn 0361-5960Article

Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer = Etude phase I de l'aziridinylbenzoquinone (AZQ, NSC 182986) chez les enfants cancéreuxTAN, C. T. C; HANCOCK, C. H; MONDORA, A et al.Cancer research (Baltimore). 1984, Vol 44, Num 2, pp 831-835, issn 0008-5472Article

Phase I study of intravenous gamma globulin in multiple myelomaGORDON, D. S; HEARN, E. B; SPIRA, T. J et al.The American journal of medicine. 1984, Vol 76, Num 3, pp 111-116, issn 0002-9343Article

Phase I evaluation of semustine in a weekly schedule = Essai phase I de la sémustine en administration hebdomadaireKOLLER, C. A; SCHWALM, D; LIEPMAN, M et al.Cancer treatment reports. 1983, Vol 67, Num 6, pp 579-581, issn 0361-5960Article

Phase I study of acivicin in patients with advanced cancer = Essai phase I de l'acivicine dans les cancers avancésSRIDHAR, K. S; OHNUMA, T; CHAHINIAN, A. P et al.Cancer treatment reports. 1983, Vol 67, Num 7-8, pp 701-703, issn 0361-5960Article